[144] Alnylam Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Alnylam Pharmaceuticals (ALNY) filed a Form 144 reporting a proposed sale of 1,455 shares of common stock through UBS Financial Services on 08/19/2025. The filing lists an aggregate market value of $664,935.00 and shows 131,079,015 shares outstanding. The securities were acquired from the issuer as PSU on 08/15/2025 with payment recorded on the same date.

The filer certifies they are not aware of undisclosed material adverse information and discloses no sales of the issuer's securities in the past three months. The filing provides broker details and the exchange (NASDAQ) where the sale is expected to occur.

Positive

• Transparent disclosure of proposed sale details including broker, date, and aggregate value
• Filer certifies absence of undisclosed material adverse information as required

Negative

• Rapid disposition: securities were acquired as PSUs on 08/15/2025 and a sale is proposed for 08/19/2025
• No additional context is provided about the reason for the sale or any trading plan dates

Insights

Financial Analyst

TL;DR: Routine insider notice of a small proposed sale, no new financial data disclosed.

This Form 144 documents a proposed disposition of 1,455 shares via a broker on 08/19/2025, following acquisition as PSUs on 08/15/2025. The filing gives transparency on timing, broker, and market value but does not provide any operational or earnings information that would affect valuation models. The disclosure is procedural and allows market participants to track insider liquidity events.

Corporate Governance Expert

TL;DR: Adequate compliance disclosure; quick sale after grant is noted but fully disclosed.

The notice meets Rule 144 disclosure norms by listing acquisition details, broker, sale date, and a representation regarding material non-public information. The close timing between acquisition and proposed sale is explicitly stated in the filing and is important for governance monitoring, but the document contains no additional governance or policy changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Avenue 4th Floor New York NY 10010	1455	664935.00	131079015	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	PSU	Issuer			1455	08/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ALNY's Form 144 report?

The filing reports a proposed sale of 1,455 common shares through UBS on 08/19/2025 with aggregate market value $664,935.00.

When were the shares acquired that are being sold (ALNY)?

The securities were acquired from the issuer as PSU on 08/15/2025 and payment is recorded the same date.

Which broker will execute the ALNY sale?

The named broker is UBS Financial Services, Inc., 11 Madison Avenue, New York, NY.

Is there any record of ALNY securities sold in the past three months?

The filing states: Nothing to Report for securities sold during the past three months.

On which exchange is the ALNY sale expected to occur?

The filing lists NASDAQ as the securities exchange for the proposed sale.